Health Assurance Acquisition Corp. will redeem its Public Shares and will not consummate an initial business combination
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Health Assurance Acquisition Corp. (the “Company”) (Nasdaq: HAAC), a special purpose acquisition company, today announced that as of the close of business on November 3, 2022, the Company’s publicly held Class A ordinary shares, par value
As stated in the Company’s Certificate of Incorporation and in the Company’s registration statement on Form S-1 (Registration No. 333-249667), initially filed with the United States Securities and Exchange Commission (the “Commission”) on October 26, 2020, relating to the Company’s initial public offering, if the Company is unable to complete an initial business combination within 24 months of the initial public offering, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to
The per-share redemption price for the Public Shares will be approximately
As of the close of business on November 3, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount on or around November 18, 2022. The Company anticipates that the Public Shares will cease trading on The Nasdaq Capital Market (“Nasdaq”) as of the close of business on November 3, 2022.
The Redemption Amount will be payable to the holders of the Public Shares upon delivery of their shares to the Company’s transfer agent, Continental Stock Transfer & Trust Company. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount.
The Company’s sponsor has agreed to waive its redemption rights with respect to its outstanding Class B common stock issued prior to the Company’s initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless. After November 3, 2022, the Company shall cease all operations except for those required to wind up the Company’s business.
The Company expects that Nasdaq will file a Form 25 with the Commission in order to delist the Company’s securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of the Company’s securities under the Securities Exchange Act of 1934, as amended.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company’s intention to redeem all of its outstanding Public Shares, the Company’s cash position or cash held in the Trust Account, the Redemption Amount or the timing when the Company’s Public Shares will cease trading on Nasdaq. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.
Contact
Sue Kwon
General Catalyst
skwon@generalcatalyst.com